Utility of BAP1 immunohistochemistry and p16 (CDKN2A) FISH in the diagnosis of malignant mesothelioma in effusion cytology specimens

American Journal of Surgical Pathology

Volumn 40, Issue 1, 2016, Pages 120-126

  Hwang, Harry C ^a   Sheffield, Brandon S ^b,c   Rodriguez, Stephanie ^a   Thompson, Kim ^a   Tse, Christopher H ^a   Gown, Allen M ^a   Churg, Andrew ^b,c  

^a PHENOPATH LABORATORIES   (United States)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

BAP1; CDKN2A FISH; cytology; malignant mesothelioma; p16 FISH

Indexed keywords

BAP1 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; PARAFFIN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN THIOLESTERASE;

AGED; BIOPSY; CELL PROLIFERATION; DOWN REGULATION; ENZYMOLOGY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; PATHOLOGY; PLEURAL EFFUSION, MALIGNANT; PREDICTIVE VALUE; PROGNOSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BIOPSY; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DOWN-REGULATION; FEMALE; GENE DELETION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; PARAFFIN EMBEDDING; PLEURAL EFFUSION, MALIGNANT; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN THIOLESTERASE;

EID: 84952631548     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000529     Document Type: Article

References (19)

1. Henderson DW, Reid G, Kao SC, et al. Challenges and controversies in the diagnosis of mesothelioma: part 1. Cytologyonly diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers. J Clin Pathol. 2013; 66: 847-853
2. Paintal A, Raparia K, Zakowski MF, et al. The diagnosis of malignant mesothelioma in effusion cytology: a reappraisal and results of a multi-institution survey. Cancer Cytopathol. 2013; 121: 703-707
3. Monaco SE, Shuai Y, Bansal M, et al. The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations. Am J Clin Pathol. 2011; 135: 619-627
4. Chung CT, Santos Gda C, Hwang DM, et al. FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma. J Clin Pathol. 2010; 63: 630-634
5. Chiosea S, Krasinskas A, Cagle PT, et al. Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas. Mod Pathol. 2008; 21: 742-747
6. Hwang H, Tse C, Rodriguez S, et al. p16 FISH deletion in surface epithelial mesothelial proliferations is predictive of underlying invasive mesothelioma. Am J Surg Pathol. 2014; 38: 681-688
7. Ito T, Hamasaki M, Matsumato S, et al. p16/CDKN2A FISH in differentiation of diffuse malignant peritoneal mesothelioma from mesothelial hyperplasia and epithelial ovarian cancer. Am J Clin Pathol. 2015; 143: 830-838
8. Wu D, Hiroshima K, Matsumoto S, et al. Diagnostic usefulness of p16/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis. Am J Clin Pathol. 2013; 139: 39-46
9. Tochigi N, Attanoos R, Chirieac LR, et al. p16 Deletion in sarcomatoid tumors of the lung and pleura. Arch Pathol Lab Med. 2013; 137: 632-636
10. BottM, Brevet M, Taylor BS, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet. 2011; 43: 668-672
11. Testa JR, Cheung M, Pei J, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2011; 43: 1022-1025
12. Murali R, Wiesner T, Scolyer RA. Tumours associated with BAP1 mutations. Pathology. 2013; 45: 116-126
13. Nasu M, Emi M, Pastorino S, et al. High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma. J Thorac Oncol. 2015; 10: 565-576
14. Sheffield BS, Hwang HC, Lee AF, et al. BAP1 Immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations. Am J Surg Pathol. 2015; 39: 977-982
15. Churg A, Galateau-Salle F. The separation of benign and malignant mesothelial proliferations. Arch Pathol Lab Med. 2012; 136: 1217-1226
16. Lee AF, Gown AM, Churg A. IMP3 and GLUT-1 immunohistochemistry for distinguishing benign from malignanct mesothelial proliferations. Am J Surg Pathol. 2013; 37: 421-426
17. Illei PB, Ladanyi M, Rusch VW, et al. The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions. Cancer. 2003; 99: 51-56
18. Onofre FB, Onofre AS, Pomjanski N, et al. 9p21 Deletion in the diagnosis of malignant mesothelioma in serous effusions additional to immunocytochemistry, DNA-ICM, and AgNOR analysis. Cancer. 2008; 114: 204-215
19. Sheffield BS, Tinker AV, Shen Y, et al. Personalized oncogenomics: clinical experience with malignant peritoneal mesothelioma using whole genome sequencing. PLoS One. 2015; 10: e0119689